Drug Profile

BMS 986470

Alternative Names: BMS-986470

Latest Information Update: 20 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bristol-Myers Squibb
Class Antianaemics; Small molecules
Mechanism of Action Apoptosis stimulants; CRBN protein modulators; Fetal haemoglobin expression modulators; Ubiquitin protein ligase modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Sickle cell anaemia

Most Recent Events

07 Dec 2024 Pharmacodynamics data from a preclinical trial in Sickle cell anaemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
17 Jul 2024 Phase-I/II clinical trials in Sickle cell anaemia in USA (PO) (NCT06481306)
17 Jul 2024 Preclinical trials in Sickle cell anaemia in USA (PO) prior to July 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com